Interspecies scaling of a camptothecin analogue: Human predictions for intravenous topotecan using animal data

References

• Beretta GL, Zunino F. Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity. Biochemical Pharmacology 2007; 74: 1427–1444
   Google Scholar
• Bhamidipathi RK, Dravid PV, Mullangi R, Srinivas NR. Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: Applicability for the development of novel oxazolidinones. Xenobiotica 2004; 36: 571–579
   Google Scholar
• Blaney SM, Cole DE, Balis FM, Godwin K, Poplack DG. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Cancer Research 1993; 53: 725–727
   PubMed Web of Science ®Google Scholar
• Boxembaun H. Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics. Journal of Pharmacokinetics and Biopharmacology 1982; 10: 201–227
   PubMedGoogle Scholar
• Burris HA, III. Topotecan; incorporating it into the treatment of solid tumors. Oncologist 1998; 3: 1–3
   PubMedGoogle Scholar
• Chatterjee A, Digumarti R, Katremi K, Upreti VV, Manidi RNVS, Mullangi R, Surath A, Srinivas ML, Uppalapati S, Jiwatani S, et al. Safety, tolerability and pharmacokinetics of a capsule formulation of DRF-1042, a novel camptothecin 12 analog, in refractory cancer patients in a bridging phase I study. Journal of Clinical Pharmacology 2005; 45: 453–460
   PubMed Web of Science ®Google Scholar
• Chen J, Lu Q, Balthasar JP. Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice. Journal of Pharmacokinetics and Pharmacodynamics 2007; 34: 829–847
   PubMedGoogle Scholar
• Clark JW. Rubitecan. Expert Opinion: Investigational Drugs 2006; 15: 71–79
   PubMed Web of Science ®Google Scholar
• Coleman RL. Emerging role of topotecan in front-line treatment of carcinoma of the ovary. Oncologist 2002; 7: 46–55
   PubMed Web of Science ®Google Scholar
• Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharmaceutical Research 1993; 10: 1093–1095
   PubMed Web of Science ®Google Scholar
• Davies BE, Minthron EA, Dennis MJ, Rosing H, Beijnen JH. The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog. Pharmaceutical Research 1997; 14: 1461–1465
   PubMed Web of Science ®Google Scholar
• De Jager R, Cheverton P, Tamanoi K, Coyle J, Ducarme M, Sakamoto N, Satomi M, Suzuli M. DX-8951f: Summary of phase I clinical trials. Annals of the New York Academy of Science 2000; 922: 260–273, DX-8951f Investigators.
   PubMedGoogle Scholar
• De Vries NA, Ouwehand M, Buckle T, Beijnen JH, Van Tellingen O. Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography. Biomedical Chromatography 2007; 21: 1191–1200
   PubMedGoogle Scholar
• El-Kareh AW, Secomb TW. Two-mechanism peak concentration model for cellular pharmacodynamics of doxorubicin. Neoplasia 2005; 7: 705–713
   PubMed Web of Science ®Google Scholar
• Fabbri F, Carloni S, Brigliadori G, Zoli W, Lapalombella R, Marini M. Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: A cytometric study. BMC Cell Biology 2006; 7: 6
   PubMed Web of Science ®Google Scholar
• Gabr A, Kuin A, Aalders M, El-Gawly H, Smets LA. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acid pH. Cancer Research 1997; 57: 4811–4816
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clinical Cancer Research 2002; 8: 641–661
   PubMed Web of Science ®Google Scholar
• Goodin S, Kane MP, Rubin EH. Epothilones: Mechanism of action and biologic activity. Journal of Clinical Oncology 2004; 22: 2015–2025
   PubMed Web of Science ®Google Scholar
• Grochow LB, Rowinsky EK, Johnson R, Ludeman S, Kaufmann SH, McCabe FL, Smith BR, Hurowitz L, DeLisa A, Donehower RC. Pharmacokinetics and Pharmacodynamics of topotecan inpatients with advanced cancer. Drug Metabolism and Disposition 1992; 20: 706–713
   PubMed Web of Science ®Google Scholar
• Hansen RJ, Ludeman SM, Paikoff SJ, Pegg AE, Dolan ME. Role of MGMT in protecting against cyclophosphamide-induced toxicity in cells and animals. DNA Repair (Amst) 2007; 6: 1145–1154
   PubMed Web of Science ®Google Scholar
• Herben VM, ten Bokkel Huinink WW, Dubbelman AC, Mandjes IA, Groot Y, Van Grotel-Van Zomeren DM, Beijen JH. Phase I and pharmacology of sequential intravenous topotecan and oral etoposide. British Journal of Cancer 1997; 76: 1500–1508
   PubMedGoogle Scholar
• Jung LL, Ramanathan RK, Egorin MJ, Jin R, Belani CP, Potter DM, Strychor S, Trump DL, Walko C, Fakih M, et al. Pharmacokinetic studies of 9-nitrocamptothecin on intermittent and continuous schedules of administration in patients with solid tumors. Cancer Chemotherapy and Pharmacology 2004; 54: 487–496
   PubMed Web of Science ®Google Scholar
• Kaur G, Hollingshead M, Holbeck S, Schauer-Vukasinovic V, Camalier RF, Domling A, Agarwal S. Biological evaluation of tubulysin A: A potential anticancer and antiangiogenic natural product. Biochemistry Journal 2006; 396: 235–242
   PubMed Web of Science ®Google Scholar
• Kim SH, Kim WB, Lee MG. Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics. Biopharmaceutics and Drug Disposition 1998; 19: 231–235
   PubMed Web of Science ®Google Scholar
• Mahmood I, Balian JD. Interspecies scaling: Predicting pharmacokinetic parameters of antiepileptic drugs in humans from animals with special emphasis on clearance. Journal of Pharmaceutical Science 1996; 85: 411–414
   PubMed Web of Science ®Google Scholar
• Mahmood I, Yuan R. A comparative study of allometric scaling with plasma concentrations predicted by species-invariant time methods. Biopharmaceutics and Drug Disposition 1999; 20: 137–144
   PubMed Web of Science ®Google Scholar
• Mehta SC, Lu RD. Interspecies pharmacokinetic scaling of BSH in mice, rats, rabbits, and humans. Biopharmaceutics and Drug Disposition 1995; 16: 735–744
   PubMed Web of Science ®Google Scholar
• Mi Z, Malak H, Burke TG. Reduced albumin binding promotes the stability and activity of topotecan in human blood. Biochemistry 1995; 35: 13722–13728
   Google Scholar
• Mustafa S, Venkatesh P, Pasha K, Mullangi R, Srinivas NR. Altered Intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: Do adenosine A1 antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF?. Xenobiotica 2006; 36: 1239–1258
   PubMed Web of Science ®Google Scholar
• O’Brien M, Eckardt J, Ramlau R. Recent advances with Topotecan in the treatment of lung Cancer. Oncologist 2008; 12: 1194–1204
   Google Scholar
• O’Reilly S, Rowinsky E, Slichenmyer W, Donehower RC, Forastiere A, Ettinger D, Chen TL, Sartorius S, Bowling K, Smith J, et al. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. Journal of the National Cancer Institute 1996; 88: 817–824
   PubMedGoogle Scholar
• Rose WC, Marathe PH, Jang GR, Monticello TM, Balasubramanian BN, Long B, Fairchild CR, Wall ME, Wani MC. Novel fluoro-substituted camptothecins: in vivo antitumor activity, reduced gastrointestinal toxicity and pharmacokinetic characterization. Cancer Chemotherapy and Pharmacology 2006; 58: 73–85
   PubMedGoogle Scholar
• Samori C, Guerrini A, Varchi G, Zunino F, Beretta GL, Femoni C, Bombardelli E, Fontana G, Battaglia A. Thiocamptothecin. Journal of Medicinal Chemistry 2008; 51: 3040–3044
   PubMed Web of Science ®Google Scholar
• Sinha VK, De Buck SS, Fenu LA, Smit JW, Nijsen M, Gilissen RA, Van Peer A, Lavrijsen K, Mackie CE. Predicting oral clearance in humans: How close can we get with allometry. Clinical Pharmacokinetics 2008; 47: 35–45
   PubMed Web of Science ®Google Scholar
• Sparreboom A, De Jonge MJ, De Bruijn P, Brouwer E, Nooter K, Loos WJ, Van Alphen RJ, Mathijssen RH, Stoter G, Verweij J. Irinotecan (CPT-11) metabolism and disposition in cancer patients. Clinical Cancer Research 1998; 4: 2747–2754
   PubMed Web of Science ®Google Scholar
• Sriram D, Yogeeswari P, Thirumurugan R, Bal TR. Camptothecin and its analogues: A review on their chemotherapeutic potential. Natural Products Research 2005; 19: 393–412
   PubMed Web of Science ®Google Scholar
• Staker BL, Hjerrild K, Feese MD, Behnke CA, Burgin AB, Jr, Stewart L. The mechanism of Topoisomerase poisoning by a camptothecin analog. Proceedings of the National Academy of Sciences. USA 2002; 99: 15387–15392
   Google Scholar
• Sung C, Blaney SM, Cole DE, Balis FM, Dedrick RL. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Cancer Research 1994; 54: 5118–5122
   PubMed Web of Science ®Google Scholar
• White SJ, Kasman LM, Kelly MM, Lu Ping, Spruill L, Mcdermott PJ, Johnson VC. Doxorubicin generates a pro-apoptotic phenotype by phosphorylation of EF-2. Free Radical Biology and Medicine 2007; 43: 1313–1321
   PubMed Web of Science ®Google Scholar
• Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama J, Yamamura T, Hashimoto-Tamaoki T. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: A novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Research 2001; 61: 1029–1037
   PubMed Web of Science ®Google Scholar
• Yount G, Yang Y, Wong B, Wang HJ, Yang LX. A novel camptothecin analog with enhanced antitumor activity. Anticancer Research 2007; 27: 3173–3178
   PubMedGoogle Scholar
• Zamboni WC, Gujjar AJ, Mandrel TD, Einhaus SL, Danks MK, Rogers WP, Heideman RL, Houghton PJ, Stewart CF. A four hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: Implications for treatment of children with metastatic medulloblastoma. Clinical Cancer Research 1998a; 4: 2537–2544
   PubMedGoogle Scholar
• Zamboni WC, Heideman RL, Meyer WH. Pharmacokinetics (PK) of topotecan in pediatric patients with normal and altered renal function. Proceedings of the American Society of Clinical Oncology 1996; 15: 180
   Google Scholar
• Zamboni WC, Hougton PJ, Johnson RK, Hulstein JL, Crom WR, Cheshire PJ, Hanna SK, Richmond LB, Xiaolong Luo, Stewart CF. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion. Journal of Pharmacology and Experimental Therapeutics 1998b; 248: 89–94
   Google Scholar
• Zamboni WC, Stewart CF, Thompson J, Santana VM, Cheshire PJ, Richmond LB, Luo X, Poquette C, Houghton JA, Houghton PJ. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts. Journal of the National Cancer Institute 1998c; 90: 505–511
   PubMedGoogle Scholar